Dasatinib: Clinical Trials

208 trials of Dasatinib, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

103 completed, 38 terminated, 21 active not recruiting, 21 unknown. 208 Phase 2, 36 Phase 1, 6 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 2208Completed 103, Terminated 38, Active not recruiting 21, Unknown 21, Recruiting 15, Withdrawn 6, Not yet recruiting 2, Enrolling by invitation 1, Suspended 1
Phase 136Completed 18, Terminated 10, Active not recruiting 2, Recruiting 2, Unknown 2, Withdrawn 2
Phase 36Recruiting 2, Active not recruiting 1, Completed 1, Unknown 1, Withdrawn 1

Follow Dasatinib: new trials by email Literature Review of Dasatinib trials Research Report on Dasatinib

Trials (filtered) newest first · largest first

All 208 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Asciminib Frontline Risk Adapted
Dasatinib 80mg QD (5 days per week), Standarc of Care - Chronic Myeloid Leukemia (CML)
Phase 2Not yet recruitingProf. Dr. med. Andreas Hochhaus2002027-01-012026-09-04
Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
Dasatinib, Ropeginterferon alfa-2b (P1101) - Chronic Myeloid Leukemia
Phase 2RecruitingM.D. Anderson Cancer Center402026-07-132026-10-13
Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blastic Transformed CML
Asciminib add-on, Imatinib, Dasatinib - Ph+ Acute Lymphoblastic Leukemia (Ph+ALL), Blastic Transformation of Chronic Myeloid Leukemia
Phase 2Not yet recruitingThe University of Hong Kong452026-03-302026-03-25
Improving Physical Ability and Cellular Senescence Elimination in HIV
Dasatinib, Quercetin, Placebo - Dasatinib - HIV, Frailty
Phase 2CompletedNational Institute of Allergy and Infectious Diseases (NIAID)822025-12-042026-11-18
HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
Dasatinib, Venetoclax, Dexamethasone - Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent
Phase 1 / Phase 2RecruitingPrincess Maxima Center for Pediatric Oncology262025-10-012025-09-16
Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Phase 2RecruitingMayo Clinic442025-09-182026-08-26
Fortifying Healthy Behaviors, Optimizing Medical Therapies and Enhancing Cognitive Function in Older Adults-pilot Study
Risk managment, Dasatinib, Quercetin (dietary supplement) - Aging, Cognitive Decline
Phase 2CompletedWashington University School of Medicine232025-07-282026-08-19
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
Biospecimen Collection, Blinatumomab, Bone Marrow Biopsy - B Acute Lymphoblastic Leukemia
Phase 2RecruitingNational Cancer Institute (NCI)2222025-05-302026-10-27
Newly-diagnosed Pediatric T-cell ALL Protocol
Venetoclax, Dasatinib, homoharringtonine - Acute Lymphoblastic Leukemia, Childhood Leukemia, Acute Lymphoblastic
Phase 2 / Phase 3RecruitingInstitute of Hematology & Blood Diseases Hospital, China6102025-03-112025-08-26
Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma
Dexamethasone, Vincristine, Inotuzumab - Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma
Phase 2RecruitingSt. Jude Children's Research Hospital1282025-01-232026-07-16
Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
Dexamethasone, Vincristine, Daunorubicin - T-cell Acute Lymphoblastic Leukemia, T-cell Lymphoma
Phase 2RecruitingSt. Jude Children's Research Hospital1002024-12-272026-08-10
Cytochrome P450 Inhibition to Decrease Dosage of Dasatinib for Chronic Myelogenous Leukemia
Dasatinib Pill, Ketoconazole Pill - Chronic Myeloid Leukemia, Chronic Phase
Phase 2UnknownHospital Universitario Dr. Jose E. Gonzalez152024-11-012022-12-06
Evaluation of DASATINIB Monotherapy Efficacy in Acute Myeloid Leukemia Patients Refractory to VENETOCLAX-AZACITIDINE
Dasatinib - Acute Myeloid Leukemia
Phase 2SuspendedInstitut Paoli-Calmettes352024-05-222026-10-01
Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast Cancer
Quercetin, Dasatinib, Taxane/Anthracycline/Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1/platinum - Triple-negative Breast Cancer
Phase 2UnknownFudan University102024-05-202024-07-08
Safety, Tolerance and Antiretroviral Activity of Dasatinib: a Pilot Clinical Trial in Patients With Recent HIV-1 Infection
Dasatinib, Placebo - Recent HIV-1 Infection
Phase 2Active not recruitingEva Bonfill242024-01-262026-07-06
Pediatric-Inspired Chemotherapy Plus Tyrosine Kinase Inhibitor in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Dasatinib, Ponatinib, Berlin-Frankfurt-Münster Chemotherapy - Acute Lymphoblastic Leukemia
Phase 2WithdrawnUniversity of Michigan Rogel Cancer Center2024-01-012024-02-22
Single Nuclei RNA-seq to Map Adipose Cellular Populations and Senescent Cells in Older Subjects
Lifestyle Intervention, Dasatinib 100 MG, Quercetin 1000mg - Obesity, Healthy Lifestyle
Phase 2 / Phase 3RecruitingCedars-Sinai Medical Center1602023-10-172026-03-18
Safety and Impact of Dasatinib on Viral Persistence and Inflammation in People With HIV Under Antiretroviral Treatment
Dasatinib 70 mg, Placebo - HIV Infection Primary
Phase 2CompletedFundació Institut Germans Trias i Pujol602023-10-162025-09-22
Senolytics to Improve Osteoporosis Therapy
Dasatinib 100 Mg Oral Tablet, Quercetin 1.250 mg (oral), Nicotinamide Riboside 1g (oral) - Osteopenia, Osteoporosis, Age-related Bone Loss
Phase 2CompletedOdense University Hospital1202023-09-062026-10-23
Dasatinib and Quercetin to Treat Fibrotic Non-alcoholic Fatty Liver Disease
Dasatinib 100 MG + Quercetin (1000 MG), Placebo - NAFLD, NASH With Fibrosis
Phase 1 / Phase 2CompletedAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)302023-07-052026-04-15

Showing 20 of 208. Sign in to see all of them.

Conditions studied

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (39)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (28)  ·  Leukemia, Myeloid, Chronic-Phase (19)  ·  Leukemia (18)  ·  Breast Neoplasms (17)  ·  Prostatic Neoplasms (11)  ·  Recurrence (11)  ·  Carcinoma, Non-Small-Cell Lung (8)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (8)  ·  Leukemia, Myeloid, Acute (8)  ·  Neoplasm Metastasis (8)  ·  Lung Neoplasms (7)  ·  Lymphoma (6)  ·  Melanoma (6)  ·  Pancreatic Neoplasms (6)

Sponsors

Bristol-Myers Squibb (31)  ·  National Cancer Institute (NCI) (23)  ·  M.D. Anderson Cancer Center (16)  ·  St. Jude Children's Research Hospital (5)  ·  Duke University (4)  ·  Washington University School of Medicine (4)  ·  Alliance for Clinical Trials in Oncology (3)  ·  City of Hope Medical Center (3)  ·  Kanto CML Study Group (3)  ·  Massachusetts General Hospital (3)  ·  Mayo Clinic (3)  ·  Memorial Sloan Kettering Cancer Center (3)  ·  Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (2)  ·  Gruppo Italiano Malattie EMatologiche dell'Adulto (2)  ·  H. Lee Moffitt Cancer Center and Research Institute (2)

Countries

United States (140)  ·  France (30)  ·  Canada (28)  ·  Italy (26)  ·  Germany (23)  ·  Spain (21)  ·  United Kingdom (17)  ·  Australia (14)  ·  Finland (14)  ·  Belgium (13)  ·  Norway (13)  ·  Sweden (12)  ·  China (11)  ·  Netherlands (11)  ·  South Korea (11)

Top investigators

Ehab Atallah, MD (2)  ·  Eric Lenze, MD (2)  ·  Nicolas Musi, MD (2)  ·  Philip Amrein, MD (2)  ·  Stacy Moulder, MD (2)  ·  Adil Daud, M.D. (1)  ·  Ahmed Aribi (1)  ·  Allen Eng Juh Yeoh, MBBS (1)  ·  Amer Zeidan (1)  ·  Ana Gonzalez-Angulo, MD, MS (1)  ·  Andrej Lissat, MD PhD (1)  ·  Andrew Lassman (1)  ·  Anjali S Advani (1)  ·  Anna Turkina, Professor (1)

Results publications

PMID 33242441, PMID 34366147, PMID 34687726, PMID 40009460, PMID 41671463, PMID 12011123, PMID 17317857, PMID 19536906, PMID 20466853, PMID 21508120, PMID 21623279, PMID 21623761, PMID 21931113, PMID 21976132, PMID 22915637, PMID 23328954, PMID 23620574, PMID 23652277, PMID 24128713, PMID 24457377, PMID 24727329, PMID 24788563, PMID 25082346, PMID 25170013, PMID 25501110, PMID 25758746, PMID 25761894, PMID 26586415, PMID 26951627, PMID 27133821, PMID 28334439, PMID 28559019, PMID 28566209, PMID 28835440, PMID 29069857, PMID 29121645, PMID 29498925, PMID 29609532, PMID 29618479, PMID 29720733, PMID 29723397, PMID 29812996, PMID 30607629, PMID 30885996, PMID 31171508, PMID 31201085, PMID 31290996, PMID 31542391, PMID 31553487, PMID 31986451

NIH funding

U10CA031946 (4), U10CA180888 (4), 2008 (3), P30CA016672 (3), U10CA032102 (3), U10CA180820 (3), N01CM00071 (2), N01CM62201 (2), N01CM62202 (2), P30CA014599 (2), P30CA015704 (2), P30CA033572 (2), U10CA027469 (2), U10CA180821 (2), U10CA180868 (2)